Camurus Initiates Clinical Trial of Product Candidate in Patients with Oral Mucositis

Camurus AB has initiated a Phase I/IIa clinical study to evaluate safety, tolerability and preliminary efficacy of CAM2028, which is an oromucosal formulation of an agent being used for topical treatment of pain in cancer patients with oral mucositis, OM.

The clinical study of CAM2028 was started in September 2005 and is conducted in cancer patients with radiotherapy-induced OM. The aims are to evaluate safety, tolerability and duration of different oromucosal drug candidate products. In addition, comparison of patient's subjective acceptability as well as preliminary evaluation of the analgesic effects is performed.

Mucositis is an inflammation and ulceration of the lining of the mouth, throat or gastrointestinal tract most commonly associated with chemotherapy or radiotherapy for cancer. OM is the most commonly experienced manifestation occurring in around 40% of cancer patients. It is a severe side effect that can limit the patient's ability to tolerate cancer therapy. In more severe cases, mucositis can be extremely painful, preventing the patient from eating and necessitating hospitalisation for re-hydration, narcotic pain medication, and/or total parenteral nutrition. The destruction of the protective mucous membrane can also place the patient at a serious risk of infection. OM is an indication with high unmet medical needs.

For further information, please contact:

Fredrik Tiberg,

President & CEO

Tel: +46 46 286 3863

Email: info@camurus.ideon.se

Or visit: www.camurus.se